Your browser is no longer supported. Please, upgrade your browser.
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.70 Insider Own0.40% Shs Outstand44.61M Perf Week0.33%
Market Cap10.71B Forward P/E- EPS next Y-8.63 Insider Trans-81.57% Shs Float33.72M Perf Month-5.93%
Income-329.20M PEG- EPS next Q-2.23 Inst Own97.10% Short Float11.28% Perf Quarter15.96%
Sales12.20M P/S877.49 EPS this Y-78.70% Inst Trans0.11% Short Ratio7.50 Perf Half Y79.11%
Book/sh12.35 P/B17.36 EPS next Y-6.00% ROA-54.20% Target Price245.92 Perf Year140.06%
Cash/sh11.60 P/C18.49 EPS next 5Y- ROE-60.00% 52W Range66.01 - 249.42 Perf YTD-2.36%
Dividend- P/FCF- EPS past 5Y-11.90% ROI- 52W High-14.02% Beta1.46
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low224.88% ATR9.22
Employees111 Current Ratio8.80 Sales Q/Q1056.30% Oper. Margin- RSI (14)45.28 Volatility2.74% 4.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-41.40% Profit Margin- Rel Volume0.64 Prev Close212.93
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume506.86K Price214.45
Recom2.30 SMA20-1.97% SMA50-5.28% SMA20037.54% Volume323,510 Change0.71%
Dec-08-20Initiated JMP Securities Mkt Perform
Dec-08-20Initiated Evercore ISI Outperform
Nov-17-20Downgrade BofA Securities Neutral → Underperform $196
Nov-10-20Downgrade Jefferies Buy → Hold $206 → $208
Nov-10-20Downgrade Guggenheim Buy → Neutral $230
Nov-09-20Reiterated H.C. Wainwright Buy $233 → $265
Sep-28-20Initiated BofA Securities Neutral $172
Sep-18-20Downgrade Citigroup Buy → Neutral $127 → $183
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Mar-12-20Upgrade JP Morgan Underweight → Neutral $88
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jan-20-21 08:00AM  
Jan-18-21 06:43AM  
Jan-12-21 08:00AM  
Jan-11-21 08:00AM  
Jan-07-21 04:43PM  
03:30PM  
08:26AM  
Jan-06-21 03:24PM  
01:52PM  
Jan-05-21 10:19AM  
Jan-04-21 05:56PM  
05:19PM  
Dec-28-20 06:37AM  
Dec-24-20 10:50AM  
08:26AM  
Dec-23-20 07:51PM  
12:01PM  
Dec-22-20 04:40PM  
10:15AM  
Dec-19-20 02:44PM  
Dec-15-20 08:53AM  
Dec-08-20 01:42PM  
12:32PM  
Dec-07-20 06:01AM  
04:43AM  
Dec-04-20 04:27PM  
11:31AM  
Dec-02-20 08:00AM  
Dec-01-20 06:58AM  
06:33AM  
Nov-28-20 08:40AM  
08:00AM  
Nov-24-20 08:00AM  
Nov-23-20 04:30PM  
08:11AM  
Nov-22-20 05:22PM  
Nov-20-20 04:27PM  
11:33AM  
Nov-19-20 02:26PM  
Nov-17-20 10:04AM  
Nov-16-20 03:13AM  
Nov-12-20 10:35AM  
Nov-08-20 09:44AM  
Nov-06-20 02:18PM  
10:50AM  
Nov-05-20 04:30PM  
08:00AM  
07:30AM  
Nov-04-20 07:05PM  
05:05PM  
04:15PM  
04:00PM  
Nov-03-20 12:21PM  
Oct-30-20 05:09PM  
10:20AM  
08:39AM  
Oct-29-20 09:13AM  
Oct-28-20 06:51PM  
04:48AM  
Oct-27-20 08:04PM  
07:53AM  
03:49AM  
Oct-26-20 04:46PM  
04:23PM  
03:13PM  
12:31PM  
12:22PM  
11:32AM  
03:02AM  
Oct-25-20 10:45AM  
Oct-24-20 06:00AM  
Oct-23-20 12:52PM  
Oct-21-20 05:17PM  
01:16PM  
08:00AM  
Oct-17-20 01:57AM  
Oct-15-20 04:30PM  
Oct-14-20 04:06PM  
Oct-13-20 04:08PM  
Oct-12-20 09:45AM  
Oct-08-20 04:28PM  
Oct-06-20 02:55PM  
01:56PM  
09:48AM  
Oct-05-20 02:06PM  
08:00AM  
Oct-01-20 04:40PM  
11:38AM  
Sep-29-20 11:30AM  
Sep-18-20 04:16PM  
04:10PM  
08:00AM  
Sep-17-20 08:01AM  
Sep-15-20 05:00PM  
09:27AM  
Sep-14-20 03:31PM  
Sep-11-20 02:16PM  
Sep-09-20 04:10PM  
05:25AM  
Sep-08-20 08:34PM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM CHARLES MPresident & CEOJan 19Option Exercise27.003,24587,615110,422Jan 20 06:17 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 07Sale216.3324152,1357,471Jan 08 07:57 PM
Hickey BenjaminEVP, Chief Commercial OfficerJan 07Sale216.332,078449,52519,789Jan 08 07:46 PM
Faga DanielEVP, Chief Operating OfficerJan 07Sale216.332,625567,85423,615Jan 08 07:15 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 06Sale210.39538113,1907,712Jan 08 07:57 PM
Christensen JamieEVP, Chief Scientific OfficerJan 06Sale210.391,459306,96147,262Jan 08 07:15 PM
BAUM CHARLES MPresident & CEOJan 06Sale210.394,511949,06687,512Jan 08 07:14 PM
BAUM CHARLES MPresident & CEODec 18Option Exercise8.4940,000339,600142,023Dec 21 06:28 PM
BAUM CHARLES MPresident & CEODec 18Sale234.4840,0009,379,114102,023Dec 21 06:28 PM
FUCHS HENRY JDirectorDec 15Option Exercise20.5410,000205,40012,000Dec 16 05:37 PM
FUCHS HENRY JDirectorDec 15Sale233.3910,0002,333,9072,000Dec 16 05:37 PM
CARTER BRUCE L ADirectorDec 14Option Exercise6.782,25015,2554,250Dec 16 05:37 PM
GREY MICHAEL GDirectorDec 14Option Exercise16.8410,900183,55615,156Dec 16 05:36 PM
GREY MICHAEL GDirectorDec 14Sale245.4410,9002,675,3454,256Dec 16 05:36 PM
CARTER BRUCE L ADirectorDec 14Sale246.282,250554,1272,000Dec 16 05:37 PM
Christensen JamieEVP, Chief Scientific OfficerNov 02Option Exercise8.3210,87990,49348,721Nov 04 05:59 PM
Boxer Capital, LLC10% OwnerOct 30Option Exercise0.00400,0034001,765,562Oct 30 09:54 PM
Boxer Capital, LLC10% OwnerOct 30Sale202.00400,00080,800,000216,288Oct 30 09:54 PM
Braslyn Ltd.10% OwnerOct 29Option Exercise0.00104,5651053,135,967Oct 30 09:53 PM
Braslyn Ltd.10% OwnerOct 29Sale213.33104,56422,306,8913,031,402Oct 30 09:53 PM
Braslyn Ltd.10% OwnerOct 28Option Exercise0.00295,4382953,135,968Oct 30 09:53 PM
Braslyn Ltd.10% OwnerOct 28Sale206.57295,43661,027,5462,840,530Oct 30 09:53 PM
CARTER BRUCE L ADirectorAug 11Option Exercise6.782,25015,2554,250Aug 13 04:03 PM
CARTER BRUCE L ADirectorAug 11Sale126.412,250284,4282,000Aug 13 04:03 PM
FUCHS HENRY JDirectorAug 10Option Exercise20.5410,000205,40012,000Aug 11 05:36 PM
FUCHS HENRY JDirectorAug 10Sale131.3810,0001,313,7832,000Aug 11 05:36 PM
Braslyn Ltd.10% OwnerJun 12Option Exercise0.00600,0066003,135,972Jun 16 05:03 PM
Braslyn Ltd.10% OwnerJun 12Sale69.00600,00041,400,0002,535,966Jun 16 05:03 PM
CARTER BRUCE L ADirectorMay 18Option Exercise6.784,00027,1206,000May 20 05:10 PM
CARTER BRUCE L ADirectorMay 18Sale106.864,000427,4402,000May 20 05:10 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Option Exercise24.9933,334833,01772,735May 13 04:18 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Sale105.0033,3343,500,07039,401May 13 04:18 PM
BAUM CHARLES MPresident & CEOApr 27Option Exercise5.405573,008107,023Apr 28 08:49 PM
Johnson Craig ADirectorApr 20Option Exercise25.8415,000387,60017,000Apr 21 05:26 PM
Johnson Craig ADirectorApr 20Sale93.0015,0001,395,0002,000Apr 21 05:26 PM
BAUM CHARLES MPresident & CEOApr 17Option Exercise8.4940,000339,600146,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOApr 17Sale90.3340,0003,613,109106,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOMar 27Option Exercise5.402,29112,371106,466Mar 30 05:52 PM
Christensen JamieEVP, Chief Scientific OfficerMar 26Option Exercise15.518,058124,98332,842Mar 27 05:37 PM
BAUM CHARLES MPresident & CEOFeb 28Option Exercise5.402,29112,371104,175Mar 02 04:28 PM
BAUM CHARLES MPresident & CEOFeb 04Option Exercise15.414,68772,247101,884Feb 06 04:41 PM
CHEN ISANEVP, Chief Medical OfficerJan 29Option Exercise24.993,00275,02039,401Jan 31 08:03 PM